MK-677 vs Ipamorelin

Overview

MK-677 (ibutamoren) and ipamorelin are both marketed as growth hormone secretagogues, but they differ significantly in their chemistry, administration, and evidence base. Neither is FDA-approved for any indication.

Important: Both compounds are sold as research chemicals. Quality, purity, and safety cannot be guaranteed.

Key Facts

Aspect	MK-677	Ipamorelin
Class	Non-peptide GHS	Peptide GHRP
Administration	Oral	Subcutaneous injection
FDA Status	Not approved	Not approved
WADA Status	Prohibited	Prohibited
Development	Clinical trials conducted	Limited clinical development

Mechanism Comparison

Aspect	MK-677	Ipamorelin
Target	Ghrelin receptor (GHSR)	GHRP receptor / GHS-R1a
Action	Ghrelin mimetic	Synthetic GHRP
GH Release	Pulsatile via hypothalamic action	Pulsatile via hypothalamic/pituitary
Oral Activity	Yes	No
Half-life	~4-6 hours (effects longer)	~2 hours

How They Work

MK-677 (Ibutamoren):

• Non-peptide compound that mimics ghrelin
• Binds to ghrelin receptors in hypothalamus and pituitary
• Stimulates GH release without affecting cortisol
• Increases IGF-1 levels

Ipamorelin:

• Synthetic pentapeptide (5 amino acids)
• Selective growth hormone releasing peptide
• Acts on pituitary somatotrophs
• Claimed to be more selective than other GHRPs

Evidence Quality

MK-677 Research

Trial Type	Status	Key Findings
Phase 1/2 in GH deficiency	Completed	Increased GH and IGF-1
Phase 2 in elderly	Completed	Some muscle/function effects
Hip fracture recovery	Completed	Mixed results
FDA Approval	Not pursued	Development discontinued

Published research:

• Multiple peer-reviewed studies exist
• Studied in elderly, GH-deficient populations
• Showed GH/IGF-1 increases but limited clinical outcomes
• Development was discontinued (not approved)

Ipamorelin Research

Trial Type	Status	Key Findings
GH secretion studies	Completed	GH release demonstrated
Gut motility studies	Completed	Some positive effects
Clinical development	Limited	No major programs completed

Published research:

• Fewer published studies than MK-677
• Some preclinical and early clinical data
• Limited independent replication
• No completed Phase 3 programs

Evidence Strength Comparison

Factor	MK-677	Ipamorelin
Peer-reviewed studies	More extensive	Limited
Human trials	Multiple completed	Few completed
Independent replication	Some	Minimal
Long-term data	Limited	Very limited
Overall quality	Low-Moderate	Low

Side Effects

MK-677 (From Clinical Trials)

Side Effect	Incidence	Concern Level
Increased appetite	Very common	Expected (ghrelin effect)
Water retention/edema	Common	Moderate
Joint pain	Common	Moderate
Increased blood glucose	Common	Significant
Insulin resistance	Reported	Significant
Fatigue/lethargy	Common	Low-Moderate

Ipamorelin (Limited Data)

Side Effect	Reported	Evidence Quality
Injection site reactions	Occasional	Anecdotal
Headache	Reported	Limited data
Flushing	Reported	Limited data
Less hunger increase	Claimed	Uncertain

Key Safety Concerns

MK-677:

• Glucose metabolism: Increased blood glucose and insulin resistance observed in clinical trials
• Long-term effects: Unknown (development discontinued)
• Theoretical cancer risk: Elevated IGF-1 has theoretical concerns

Ipamorelin:

• Purity concerns: No pharmaceutical-grade product available
• Dosing uncertainty: No standardized protocols
• Long-term effects: No data

Practical Comparison

Factor	MK-677	Ipamorelin
Route	Oral	Injection
Convenience	Higher	Lower
Reconstitution needed	No	Yes
Source reliability	Variable	Variable

Claimed Uses (Not Approved)

Both are marketed for (without FDA approval):

• Increased growth hormone levels
• Muscle growth/preservation
• Fat loss
• Improved recovery
• Anti-aging effects

Evidence for these claims: Limited to absent for clinical endpoints. Most claims extrapolate from GH/IGF-1 increases to assumed functional benefits.

Why Neither Is Approved

MK-677

• Clinical trials showed GH/IGF-1 increases
• Failed to demonstrate sufficient clinical benefit in target populations
• Safety concerns (glucose metabolism)
• Development discontinued by manufacturer

Ipamorelin

• Never advanced through full clinical development
• No completed Phase 3 trials
• No pharmaceutical company pursuing approval

Regulatory Status

Aspect	MK-677	Ipamorelin
FDA	Not approved	Not approved
WADA	Prohibited (S2)	Prohibited (S2)
Legal status	Research chemical	Research chemical
Prescription available	No	No

Summary

Both MK-677 and ipamorelin are unapproved growth hormone secretagogues:

Factor	MK-677	Ipamorelin
Evidence quality	Low-Moderate	Low
Oral availability	Yes	No
Clinical trial data	More extensive	Limited
Known side effects	Better characterized	Less characterized
Approval status	Not approved	Not approved

Neither is recommended for human use outside of clinical trials. Products sold as research chemicals have uncertain purity, dosing, and safety.

---

This comparison is for educational purposes only. Neither compound is FDA-approved. Consult a healthcare provider before considering any research compounds.